

Lect. ESRA TUNÇ

Personal Information

Office Phone: [+90 312 595 6107](tel:+903125956107)

Email: yurdcu@ankara.edu.tr

Other Email: esrayurdcu@gmail.com

Web: <https://avesis.ankara.edu.tr/yurdcu>

Address: Ankara Üniversitesi, Tıp Fakültesi Cebeci Hastanesi, Gastroenteroloji Bilim Dalı 4. Kat Hepatoloji Enstitüsü Dikimevi-
Ankara

International Researcher IDs

ORCID: 0000-0002-1441-6408

Publons / Web Of Science ResearcherID: E-5802-2019

ScopusID: 57204863986

Yoksis Researcher ID: 368974

Education Information

Doctorate, Ankara University, Biyoteknoloji Enstitüsü, Biyoteknoloji Anabilim Dalı, Turkey 2018 - Continues

Postgraduate, Ankara University, Biyoteknoloji Enstitüsü, Biyoteknoloji Anabilim Dalı, Turkey 2014 - 2017

Undergraduate, Gazi University, Fen Fakültesi, Biyoloji, Turkey 2001 - 2005

Research Areas

Biotechnology, Virology, Molecular Biology and Genetics

Academic Titles / Tasks

Lecturer, Ankara University, Hepatoloji Enstitüsü, 2022 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Chronic hepatitis delta with normal ALT and hepatitis D viremia: unravelling its natural history**
Gulnar M. O., Kamal H., Palom A., Arici S., Esteban R., TUNÇ E., KESKİN O., İDİLMAN R., Buti M., Aleman S., et al.
JOURNAL OF HEPATOLOGY, 2024 (SCI-Expanded)
- II. **The role of PAGE-B score in predicting the development of hepatocellular cancer in patients with chronic delta hepatitis**
KESKİN O., Kalkan C., ÖZTÜRK B., Caliskan A., Sahin H., Gumussoy M., Yurdcu E., Bozdayi M., Akyildiz M., Zeybel M., et al.
JOURNAL OF HEPATOLOGY, vol.78, 2023 (SCI-Expanded)
- III. **Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta**
Kalkan Ç., Yılmaz Y., Erdoğan B. D., SAVAŞ B., Yurdcu E., Çalışkan A., Keskin O., Gencdal G., Zeybel M., TÖRÜNER M., et al.
Journal of Viral Hepatitis, vol.30, no.5, pp.406-416, 2023 (SCI-Expanded)
- IV. **FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA**

Yurdaydin C., Yurdcu E., Gumussoy M., KESKİN O., Gencdal G., Akyildiz M., Zeybel M., İDİLMAN R., Bozdayi M., Choong I., et al.

HEPATOLOGY, vol.76, 2022 (SCI-Expanded)

V. **A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis**

Yurdaydin C., Keskin O., Yurdcu E., Caliskan A., Onem S., Karakaya F., Kalkan C., Karatayli E., Karatayli S., Choong I., et al.

HEPATOLOGY, vol.75, no.6, pp.1551-1565, 2022 (SCI-Expanded)

VI. **Molecular epidemiology of Hepatitis B virus, Hepatitis C virus, and Hepatitis D virus in general population of Afghanistan**

Husseini A. A., Saeed K. M. I., Yurdcu E., BOZDAYI A. M.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.9, pp.658-666, 2020 (SCI-Expanded)

VII. **HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits**

Yasar O., Karatayli E., Cengiz G., Kizilpinar M., Yurdcu E., ALBAYRAK DELİALİOĞLU R., GÜVEN A., ARSLAN Ö., Karahan C., OTLU B., et al.

JOURNAL OF MEDICAL VIROLOGY, vol.91, no.12, pp.2174-2181, 2019 (SCI-Expanded)

VIII. **Epidemiology of blood-borne viral infections in Afghanistan**

Husseini A. A., Saeed K. M. I., Yurdcu E., SERTÖZ Ş. R., BOZDAYI A. M.

ARCHIVES OF VIROLOGY, vol.164, no.8, pp.2083-2090, 2019 (SCI-Expanded)

IX. **Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016**

Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Kocak A. A., Karatayli S. C., Yurdcu E., Yildirim U., Guriz H., BOZDAYI G., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.30, no.11, pp.957-963, 2019 (SCI-Expanded)

X. **Evaluation of 2015-2016 MOTAKK HBV DNA and HCV RNA External Quality Assessment National Program Results**

Karatayli E., Soydemir E., Aksoy Z. B., Kizilpinar M., Altay Kocak A., Karatayli S. C., Yurdcu E., Yildirim U., Guriz H., BOZDAYI G., et al.

MIKROBİYOLOJİ BULTENİ, vol.52, no.4, pp.348-366, 2018 (SCI-Expanded)

Articles Published in Other Journals

I. **A brief communication of patients with homozygous C282Y mutation-related hereditary hemochromatosis**

GÖKCAN H., Oz D., BODAKÇI E., TUNÇ E., İDİLMAN R.

HEPATOLOGY FORUM, vol.5, no.3, pp.161-164, 2024 (ESCI)

II. **Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping**

Akinci E., Yurdcu E., Orkun Ozbay B., Bodur H.

VIRAL HEPATIT DERGİSİ-VIRAL HEPATITIS JOURNAL, vol.24, no.3, pp.96-98, 2018 (ESCI)

Papers Published in Refereed Scientific Meetings

I. **NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY**

Yurdaydin C., Keskin O., Yurdcu E., Yakut M., Seven G., Kabacam G., ÖNDER F. O., Bektas M., Bozdayi M., İDİLMAN R. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

II. **TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATIT B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS**

ŞAH ÜNAL F. T., Keskin O., Yurdcu E., Yilmaz Y., KARAKAYA M. F., Kartal A., Bozdayi M., İDİLMAN R., Yurdaydin C.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70

- III. **10 YILLIK PROSPEKTİF ÇALIŞMADA DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARI REAKTİVASYONDAN ZİYADE HBSAG KAYBETMEYE YATKINDIR.**
KESKİN O., YAKUT M., YURDCU E., KALKAN Ç., AGAYEVA S., YILMAZ Y., BEKTAŞ M., BOZDAYI A. M., İDİLMAN R., YURDAYDIN S. C.
12. ULUSAL HEPATOLOJİ KONGRESİ, Antalya, Turkey, 1 - 05 May 2019
- IV. **Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study**
Hardtke S., Wedemeyer H., Caruntu F. A., Curescu M., Kendal Y., AKARCA U. S., Yurdcu E., GÜREL S., Zeuzem S., Erhardt A., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70
- V. **HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit**
Yasar O., Cengiz G., Karatayli E., Kizilpinar M., Yurdcu E., ALBAYRAK DELİALİOĞLU R., GÜVEN A., ARSLAN Ö., KARAHAN Z. C., OTLU B., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Austria, 10 - 14 April 2019, vol.70
- VI. **Comparison of the efficacy of short term and long term nucleos(t)ide analog treatment in chronic delta hepatitis**
YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., YILMAZ Y., ÇALIŞKAN KARTAL A., MELEKOĞLU ELLİK Z., YURDCU E., BOZDAYI A. M., İDİLMAN R.
35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Turkey, 21 November 2018
- VII. **Nonnasve Fbross Scores Are Not Useful for Predcton of Response to Treatment n Chronc Delta Hepatts**
KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., İDİLMAN R., YURDAYDIN S. C.
AASLD LIVER MEETING 2018, San-Francisco, Costa Rica, 9 - 13 November 2018
- VIII. **Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis**
Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., İDİLMAN R., Yurdaydin C., Keskin O.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68
- IX. **A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-analysis from the LOWR HDV-2 study using the robogene (R) real-time qPCR HDV RNA assay**
Yurdaydin C., Idilman R., Keskin O., Kalkan C., Karakaya F. M., Caliskan A., Yurdcu E., Karatayli S. C., Bozdayi M. A., Kazempour K., et al.
16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, Canada, 14 - 17 June 2018, vol.25, pp.10
- X. **Value of non-invasive fibrosis markers in chronic hepatitis D**
Kalkan C., Karakaya F., Keskin O., Kartal A., Karatayli E., Bozdayi M., Idilman R., Yurdcu E., Yurdaydin C.
International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Netherlands, 19 - 23 April 2017, vol.66
- XI. **A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study**
Yurdaydin C., Idilman R., Keskin O., Kalkan C., Karakaya M. F., Caliskan A., Yurdcu E., Karatayli S. C., Bozdayi M., Koh C., et al.
International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Netherlands, 19 - 23 April 2017, vol.66
- XII. **The prenylation inhibitor lonafarnib can induce post-treatment viral clearance in patients with**

chronic delta hepatitis resulting in alt normalization and regression of fibrosis

Yurdaydin C., Idilman R., Kalkan C., Karakaya M. F., Caliskan A., Keskin O., Yurdcu E., Karatayli S. C., Bozdayi M., Koh C., et al.

International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, Netherlands, 19 - 23 April 2017, vol.66

Metrics

Publication: 24

Citation (WoS): 82

Citation (Scopus): 51

H-Index (WoS): 5

H-Index (Scopus): 3